HomeNewsLabeling for Hereditary Issue X Deficiency Remedy Coagadex Up to date
Posted in News on 27th September 2018
The FDA has approved an expanded indication for perioperative management of bleeding

The FDA has approved an expanded indication for perioperative management of bleeding

The Food and Drug Administration (FDA) has approved updated labeling for Coagadex (coagulation factor X [human]; Bio Products Laboratory) to remove age restrictions for the currently approved indications and to add an indication for routine prophylaxis to prevent or reduce the frequency of bleeding episodes. In addition, the FDA has approved an expanded indication for perioperative management of bleeding to include patients with moderate hereditary Factor X deficiency.

Coagadex is now indicated in adults and children with hereditary Factor X deficiency for:

In an open-label, non-randomized clinical trial, the use of Coagadex in routine prophylaxis of bleeding episodes was evaluated in 9 children <12 years of age. Investigators’ assessment following 6 months of routine prophylaxis was rated “excellent” (no minor or major bleeds during the study period) in all 9 subjects. In addition, 22 infusions were given to treat a bleed, equivalent to 2.1 bleeds per subject per year; all bleeds were treated with a single infusion and recorded efficacy ratings were categorized as “excellent” (ie, bleeding stopped with 12 hours).

Related Post for New antibody can scale back swelling assaults in sufferers with hereditary angioedema

Botulinum toxin injections present promise to suppress postoperative atrial fibrillation
FDA: Critical Aspect Impact of AML Drug Not Being Acknowledged
New ointment for treating brown recluse spider bites is examined on people
FDA: MS Drug Linked to Circumstances of Stroke, Blood Vessel Wall Tears
New antibody can scale back swelling assaults in sufferers with hereditary angioedema